OssDsign

The extraordinary general meeting resolved (i) to adopt the board's proposed resolution on a long-term incentive program for employees and contractors including a directed issue of warrants and approval of transfer of warrants; and (ii) to adopt the resolution proposed by certain shareholders regarding a long-term incentive programme for board members including a directed issue of warrants and approval of transfer of warrants.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com

Certified Adviser:

Carnegie Investment Bank AB (publ) is the Company’s Certified Adviser.

Publication
This information was submitted for publication, through the agency of the contact persons set out above, on 18 December 2024, 11:10 CET.

About OssDsign

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.